Perhaps a game-changer in the safety profile of nex-z: $NTLA and partner $REGN have identified a potential critical HLA genotype for hepatocyte injury, an insight that is being utilized in enrollment of remaining p3 studies.
Such associations have been observed before (e.g. Exanta) but the positive predictive values have always been too low for HLA screening to be useful in clinical practice (e.g. 2-4*higher risk).
